Cantor Fitzgerald downgraded Esperion (ESPR) to Neutral from Overweight with a $3.16 price target after funds managed by Archimed announced a deal to acquire Esperion for $3.16 per share in cash at closing, plus the right to participate in contingent milestone payments of up to $100M in the aggregate tied to future net sales performance.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESPR:
- Esperion to be acquired by Archimed for $3.16 per share, one CVR
- Esperion Therapeutics: Reinforced Buy Rating on Strengthened Investment Story and Conference-Driven Upside Catalysts
- Esperion Completes Corstasis Acquisition, Expands Cardiovascular Portfolio
- Esperion, Athyrium Capital enter $50M royalty financing agreement
- Esperion Therapeutics Earnings Call Signals Expansion